AOD-9604 Side Effects: Severity Distribution by Patient Phenotype

Why there is no severity distribution

The obesity program is described in a 2026 review. It reports that a 24-week study (534 enrolled, 502 randomized) of oral AOD9604 failed to show significant benefit on the primary weight-loss endpoint. It notes that this conclusion rests on sponsor-reported phase 2 results rather than peer-reviewed randomized trials [3]. The same review concludes that human evidence on AOD-9604 is limited and largely short-term [3]. That evidence does not establish how severe adverse events were in different patient groups.

AOD-9604 was developed for obesity, with phase IIa trials underway by February 2002 [2]. The obesity program was later dropped [3].

What FDA has said

FDA lists AOD-9604 among bulk substances previously in its category 2 table whose nominators withdrew them. The agency's stated concerns are that compounded drugs containing AOD-9604 may pose significant immunogenicity risk for certain routes of administration due to peptide impurities and characterization problems, that it has identified no or only limited safety information, and that it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear [1]. Withdrawal from category 2 came from the nominator, not from a finding that the substance is safe [1]. FDA does not identify the events or give rates, severity grades or a breakdown by patient phenotype [1].

The oral trial and the injected products

The 24-week study tested an oral drug candidate. No efficacy trials of the injected products sold for self-administration have been identified [3]. A separate 2026 review of unapproved peptides used in sports medicine found rigorous human safety data scarce across the group and noted potential for serious harm [7].

Animal findings do not transfer

In obese Zucker rats, oral AOD9604 at 500 microgram/kg/day for 19 days cut weight gain to 15.8 g versus 35.6 g in controls and did not worsen insulin sensitivity on euglycemic clamp [8]. In obese mice, 14 days of treatment reduced body weight and body fat, and the long-term effect was absent in mice lacking the beta-3 adrenergic receptor [9]. Preclinical work found no growth-hormone-receptor binding and no cell proliferation through that receptor, unlike hGH [3][10]. None of this describes human tolerability or which patients tolerate the peptide worse.

What a patient can take from this

AOD-9604 is an unapproved growth hormone fragment with a limited human evidence base. FDA has flagged serious adverse events of unclear cause plus an immunogenicity concern for certain routes [1][3]. It is not known which events those were, how often they occurred, or whether gray-market injected product behaves like the oral drug that was studied [3].